Silver Oak Securities Incorporated Acquires 17,330 Shares of Eli Lilly and Company $LLY

Silver Oak Securities Incorporated boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 373.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,966 shares of the company’s stock after acquiring an additional 17,330 shares during the period. Eli Lilly and Company comprises about 1.8% of Silver Oak Securities Incorporated’s investment portfolio, making the stock its 5th biggest holding. Silver Oak Securities Incorporated’s holdings in Eli Lilly and Company were worth $25,416,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Coastal Bridge Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $2,959,000. Birinyi Associates Inc. boosted its stake in Eli Lilly and Company by 32.6% during the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after purchasing an additional 359 shares during the period. Bernicke Wealth Management Ltd. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $5,001,000. Mosaic Family Wealth Partners LLC grew its position in Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Finally, Trillium Asset Management LLC grew its position in Eli Lilly and Company by 1,302.8% in the 3rd quarter. Trillium Asset Management LLC now owns 5,036 shares of the company’s stock worth $5,831,000 after purchasing an additional 4,677 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.0%

Shares of NYSE:LLY opened at $1,444.05 on Monday. The company has a 50 day moving average of $1,242.25 and a 200-day moving average of $1,110.30. The firm has a market cap of $1.36 trillion, a P/E ratio of 46.87, a P/E/G ratio of 1.73 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,460.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the business earned $7.02 earnings per share. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. As a group, analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Key Eli Lilly and Company News

Investors following LLY have been watching these news items:

  • Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
  • Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study
  • Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LLY shares. Leerink Partners lifted their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday, October 21st. Citigroup increased their price objective on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. Scotiabank lifted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. Finally, TD Cowen reiterated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Read Our Latest Stock Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.